AI-powered gene technology gets money

Wednesday 19 May 2021

United States

Dyno Therapeutics Inc, based in Cambridge, Massachusetts, US, has raised $100 million in a Series A financing round to expand its technology platform for designing adeno-associated virus (AAV) vectors for gene therapies. The company is using artificial intelligence to improve the performance of capsids, the cell-targeting protein shells of AAV vectors.